Retacrit ®, Biosimilar of Epoetin alfa, in Chemotherapy-Induced Anemia in Routine Practice: Impact of Iron Supplementation

Introduction. To evaluate in real-life conditions the effectiveness and safety of a biosimilar of epoetin alpha (Retacrit ®) in chemotherapy-induced anemia and the impact of iron supplementation. Methods. This was a longitudinal, observational, prospective study of 12–16 weeks conducted in 195 French centers. The primary endpoint was the achievement of target Hb (with an increase of Hb 1 g/dL) or an increase of H b 2 g/dL, in the absence of transfusion in the previous 3 weeks. Results. 2076 patients (women, 50.6%; mean age, 67.0 years) with malignant diseases (solid tumors, 79.8%; lymphomas, 12.7%; multiple myeloma, 6.6%) were analyzed. A total of 655 patients received oral iron (40.5%), intravenous iron (58.9%) or both (0.6%). At inclusion, 10.0% and 18.2% of patients without and with iron supplementation had serum ferritin
Source: Oncology - Category: Cancer & Oncology Source Type: research